조기 암 감지 및 모니터링용 액체생검 시장 규모, 점유율, 동향 분석 보고서 : 바이오마커별, 기술별, 암별, 최종 용도별, 지역별, 부문별 예측(2025-2033년)

Liquid Biopsy For Early Cancer Detection And Monitoring Market Summary

The global liquid biopsy for early cancer detection and monitoring market size was estimated at USD 2.23 billion in 2024 and is projected to reach USD 6.20 billion by 2033, growing at a CAGR of 12.14% from 2025 to 2033. This market focuses on diagnostic solutions designed for the early and accurate detection of various cancers, enabling timely intervention and improved patient outcomes.

Technologies within this segment include platforms for analyzing circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and other biomarkers from body fluids, offering a less invasive alternative to tissue biopsies. These solutions are increasingly integrated into oncology practices for early detection, therapy selection, and disease monitoring across clinical and research environments.

The adoption of liquid biopsy is supported by rising cancer incidence and the growing need for non-invasive methods that allow frequent monitoring with minimal discomfort to patients. The ability to detect tumor-related genetic changes in real time provides oncologists with valuable information for treatment decisions and early intervention strategies.

Moreover, the adoption of liquid biopsy is increasing as the field moves toward precision oncology, where genomic and molecular insights inform treatment decisions and long-term care. High-sensitivity techniques supported by next-generation sequencing, digital PCR workflows, and advancing bioinformatics tools help detect low-frequency variants, minimal residual disease, and emerging resistance signals. Additionally, efforts in multi-cancer early detection and assay panels that analyze multiple biomarkers such as DNA, RNA fragments, epigenetic signatures, and extracellular vesicle content are broadening clinical applications from late-stage management to risk assessment and population-level screening.

Furthermore, the market is shaped by evidence-generation programs, regulatory support, and payer assessments that focus on clinical value and cost-effectiveness compared to traditional tissue-based methods. Challenges still exist, such as variations in assay performance across platforms, a lack of standardization in sample collection and analysis, and difficulties in interpreting weak signals in early disease stages. Limited reimbursement in some regions also impacts accessibility. Ongoing clinical trials, real-world studies, and data-sharing initiatives are expected to bring clarity, improve guidelines, and promote wider adoption of liquid biopsy for early detection and continuous cancer monitoring.

Innovation in liquid biopsy for early detection and monitoring emphasizes accuracy, accessibility, and clinical applicability. Multi-omics integration, AI-driven interpretation, and advanced sequencing transform detection and tracking processes, enabling higher sensitivity for early-stage disease and more personalized treatment planning.

Developments such as multi-cancer detection assays and near-patient platforms aim to extend liquid biopsies outside centralized facilities, enhancing convenience and supporting large-scale screening initiatives. Progress in minimal residual disease detection and continuous monitoring is expected to drive broader clinical uptake and strengthen liquid biopsy's role in oncology care.

Global Liquid Biopsy For Early Cancer Detection And Monitoring Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global liquid biopsy for early cancer detection and monitoring market based on biomarker, technology, cancer, end use, and region:

• Biomarker Outlook (USD Million; 2021 - 2033)
• Circulating Tumor DNA (ctDNA)
• Circulating Tumor Cells (CTCs)
• Exosomes/Microvesicles
• Circulating Proteins
• Technology Outlook (USD Million; 2021 - 2033)
• NGS (Next-Generation Sequencing)
• PCR-based assays (Digital PCR, RT-PCR)
• Microarray
• Epigenomics / Methylation assays
• Others
• Cancer Outlook (USD Million; 2021 - 2033)
• Lung Cancer
• Breast Cancer
• Colorectal Cancer
• Prostate Cancer
• Others
• End Use Outlook (USD Million; 2021 - 2033)
• Hospitals
• Diagnostic Laboratories
• Others
• Regional Outlook (USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Liquid Biopsy For Early Cancer Detection And Monitoring Market: Methodology And Scope

• 1.1. Market Segmentation And Scope
  • 1.1.1. Segment Definitions
    • 1.1.1.1. Biomarker Segment
    • 1.1.1.2. Technology Segment
    • 1.1.1.3. Cancer Segment
    • 1.1.1.4. End Use Segment
• 1.2. Regional Scope
• 1.3. Estimates And Forecast Timeline
• 1.4. Objectives
  • 1.4.1. Objective - 1
  • 1.4.2. Objective - 2
  • 1.4.3. Objective - 3
• 1.5. Research Methodology
• 1.6. Information Procurement
  • 1.6.1. Purchased Database
  • 1.6.2. Gvr's Internal Database
  • 1.6.3. Secondary Sources
  • 1.6.4. Primary Research
• 1.7. Information Or Data Analysis
  • 1.7.1. Data Analysis Models
• 1.8. Market Formulation & Validation
• 1.9. Model Details
  • 1.9.1. Commodity Flow Analysis
• 1.10. List Of Secondary Sources
• 1.11. List Of Abbreviations

Chapter 2. Liquid Biopsy For Early Cancer Detection And Monitoring Market: Executive Summary

• 2.1. Market Snapshot
• 2.2. Biomarker And Technology Snapshot
• 2.3. Cancer Snapshot
• 2.4. End Use Snapshot
• 2.5. Competitive Landscape Snapshot

Chapter 3. Liquid Biopsy For Early Cancer Detection And Monitoring Market Variables, Trends, & Scope

• 3.1. Market Segmentation And Scope
• 3.2. Market Lineage Outlook
  • 3.2.1. Parent Market Outlook
  • 3.2.2. Related/Ancillary Market Outlook
• 3.3. Market Dynamics
• 3.4. Market Drivers Analysis
  • 3.4.1. Growing Demand For Non-Invasive Cancer Screening
  • 3.4.2. Integration Of Advanced Technologies
  • 3.4.3. Increasing Clinical Adoption And Regulatory Approvals
• 3.5. Market Restraint Analysis
  • 3.5.1. High Cost Of Liquid Biopsy Tests And Infrastructure
  • 3.5.2. Analytical And Clinical Validation Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. Pestle Analysis
• 3.8. Pipeline Analysis

Chapter 4. Liquid Biopsy For Early Cancer Detection And Monitoring Market: Biomarker Estimates & Trend Analysis

• 4.1. Liquid Biopsy For Early Cancer Detection And Monitoring Market: Biomarker Movement Analysis
• 4.2. Circulating Tumor Dna (Ctdna)
  • 4.2.1. Market Estimates And Forecasts, 2021 - 2033 (USD Million)
• 4.3. Circulating Tumor Cells (Ctcs)
  • 4.3.1. Market Estimates And Forecasts, 2021 - 2033 (USD Million)
• 4.4. Exosomes/Microvesicles
  • 4.4.1. Market Estimates And Forecasts, 2021 - 2033 (USD Million)
• 4.5. Circulating Proteins
  • 4.5.1. Market Estimates And Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Liquid Biopsy For Early Cancer Detection And Monitoring Market: Technology Estimates & Trend Analysis

• 5.1. Liquid Biopsy For Early Cancer Detection And Monitoring Market: Technology Movement Analysis
• 5.2. Ngs (Next-Generation Sequencing)
  • 5.2.1. Market Revenue Estimates And Forecasts, 2021 - 2033 (USD Million)
• 5.3. Pcr-Based Assays (Digital Pcr, Rt-Pcr)
  • 5.3.1. Market Revenue Estimates And Forecasts, 2021 - 2033 (USD Million)
• 5.4. Microarray
  • 5.4.1. Market Revenue Estimates And Forecasts, 2021 - 2033 (USD Million)
• 5.5. Epigenomics / Methylation Assays
  • 5.5.1. Market Revenue Estimates And Forecasts, 2021 - 2033 (USD Million)
• 5.6. Others
  • 5.6.1. Market Revenue Estimates And Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Liquid Biopsy For Early Cancer Detection And Monitoring Market: Cancer Estimates & Trend Analysis

• 6.1. Liquid Biopsy For Early Cancer Detection And Monitoring Market: Cancer Movement Analysis
• 6.2. Lung Cancer
  • 6.2.1. Market Revenue Estimates And Forecasts, 2021 - 2033 (USD Million)
• 6.3. Breast Cancer
  • 6.3.1. Market Revenue Estimates And Forecasts, 2021 - 2033 (USD Million)
• 6.4. Colorectal Cancer
  • 6.4.1. Market Revenue Estimates And Forecasts, 2021 - 2033 (USD Million)
• 6.5. Prostate Cancer
  • 6.5.1. Market Revenue Estimates And Forecasts, 2021 - 2033 (USD Million)
• 6.6. Others
  • 6.6.1. Market Revenue Estimates And Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Liquid Biopsy For Early Cancer Detection And Monitoring Market: End Use Estimates & Trend Analysis

• 7.1. Liquid Biopsy For Early Cancer Detection And Monitoring Market: End Use Movement Analysis
• 7.2. Hospitals
  • 7.2.1. Market Revenue Estimates And Forecasts, 2021 - 2033 (USD Million)
• 7.3. Diagnostic Laboratories
  • 7.3.1. Market Revenue Estimates And Forecasts, 2021 - 2033 (USD Million)
• 7.4. Others
  • 7.4.1. Market Revenue Estimates And Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Liquid Biopsy For Early Cancer Detection And Monitoring Market: Regional Business Analysis

• 8.1. Regional Market Snapshot
• 8.2. North America
  • 8.2.1. North America Liquid Biopsy For Early Cancer Detection And Monitoring Market Estimates And Forecast, 2021 - 2033 (USD Million)
  • 8.2.2. U.S.
    • 8.2.2.1. U.S. Liquid Biopsy For Early Cancer Detection And Monitoring Market, 2021 - 2033 (USD Million)
    • 8.2.2.2. Key Country Dynamics
    • 8.2.2.3. Regulatory Framework
    • 8.2.2.4. Reimbursement Scenario
    • 8.2.2.5. Competitive Scenario
  • 8.2.3. Canada
    • 8.2.3.1. Canada Liquid Biopsy For Early Cancer Detection And Monitoring Market, 2021 - 2033 (USD Million)
    • 8.2.3.2. Key Country Dynamics
    • 8.2.3.3. Regulatory Framework
    • 8.2.3.4. Reimbursement Scenario
    • 8.2.3.5. Competitive Scenario
  • 8.2.4. Mexico
    • 8.2.4.1. Mexico Liquid Biopsy For Early Cancer Detection And Monitoring Market, 2021 - 2033 (USD Million)
    • 8.2.4.2. Key Country Dynamics
    • 8.2.4.3. Regulatory Framework
    • 8.2.4.4. Reimbursement Scenario
    • 8.2.4.5. Competitive Scenario
• 8.3. Europe
  • 8.3.1. Europe Liquid Biopsy For Early Cancer Detection And Monitoring Market, 2021 - 2033 (USD Million)
  • 8.3.2. UK
    • 8.3.2.1. UK Liquid Biopsy For Early Cancer Detection And Monitoring Market, 2021 - 2033 (USD Million)
    • 8.3.2.2. Key Country Dynamics
    • 8.3.2.3. Regulatory Framework
    • 8.3.2.4. Reimbursement Scenario
    • 8.3.2.5. Competitive Scenario
  • 8.3.3. Germany
    • 8.3.3.1. Germany Liquid Biopsy For Early Cancer Detection And Monitoring Market, 2021 - 2033 (USD Million)
    • 8.3.3.2. Key Country Dynamics
    • 8.3.3.3. Regulatory Framework
    • 8.3.3.4. Reimbursement Scenario
    • 8.3.3.5. Competitive Scenario
  • 8.3.4. Spain
    • 8.3.4.1. Spain Liquid Biopsy For Early Cancer Detection And Monitoring Market, 2021 - 2033 (USD Million)
    • 8.3.4.2. Key Country Dynamics
    • 8.3.4.3. Regulatory Framework
    • 8.3.4.4. Reimbursement Scenario
    • 8.3.4.5. Competitive Scenario
  • 8.3.5. France
    • 8.3.5.1. France Liquid Biopsy For Early Cancer Detection And Monitoring Market, 2021 - 2033 (USD Million)
    • 8.3.5.2. Key Country Dynamics
    • 8.3.5.3. Regulatory Framework
    • 8.3.5.4. Reimbursement Scenario
    • 8.3.5.5. Competitive Scenario
  • 8.3.6. Italy
    • 8.3.6.1. Italy Liquid Biopsy For Early Cancer Detection And Monitoring Market, 2021 - 2033 (USD Million)
    • 8.3.6.2. Key Country Dynamics
    • 8.3.6.3. Regulatory Framework
    • 8.3.6.4. Reimbursement Scenario
    • 8.3.6.5. Competitive Scenario
  • 8.3.7. Denmark
    • 8.3.7.1. Denmark Liquid Biopsy For Early Cancer Detection And Monitoring Market, 2021 - 2033 (USD Million)
    • 8.3.7.2. Key Country Dynamics
    • 8.3.7.3. Regulatory Framework
    • 8.3.7.4. Reimbursement Scenario
    • 8.3.7.5. Competitive Scenario
  • 8.3.8. Sweden
    • 8.3.8.1. Sweden Liquid Biopsy For Early Cancer Detection And Monitoring Market, 2021 - 2033 (USD Million)
    • 8.3.8.2. Key Country Dynamics
    • 8.3.8.3. Regulatory Framework
    • 8.3.8.4. Reimbursement Scenario
    • 8.3.8.5. Competitive Scenario
  • 8.3.9. Norway
    • 8.3.9.1. Norway Liquid Biopsy For Early Cancer Detection And Monitoring Market, 2021 - 2033 (USD Million)
    • 8.3.9.2. Key Country Dynamics
    • 8.3.9.3. Regulatory Framework
    • 8.3.9.4. Reimbursement Scenario
    • 8.3.9.5. Competitive Scenario
• 8.4. Asia Pacific
  • 8.4.1. Asia-Pacific Liquid Biopsy For Early Cancer Detection And Monitoring Market, 2021 - 2033 (USD Million)
  • 8.4.2. Japan
    • 8.4.2.1. Japan Liquid Biopsy For Early Cancer Detection And Monitoring Market, 2021 - 2033 (USD Million)
    • 8.4.2.2. Key Country Dynamics
    • 8.4.2.3. Regulatory Framework
    • 8.4.2.4. Reimbursement Scenario
    • 8.4.2.5. Competitive Scenario
  • 8.4.3. China
    • 8.4.3.1. China Liquid Biopsy For Early Cancer Detection And Monitoring Market, 2021 - 2033 (USD Million)
    • 8.4.3.2. Key Country Dynamics
    • 8.4.3.3. Regulatory Framework
    • 8.4.3.4. Reimbursement Scenario
    • 8.4.3.5. Competitive Scenario
  • 8.4.4. India
    • 8.4.4.1. India Liquid Biopsy For Early Cancer Detection And Monitoring Market, 2021 - 2033 (USD Million)
    • 8.4.4.2. Key Country Dynamics
    • 8.4.4.3. Regulatory Framework
    • 8.4.4.4. Reimbursement Scenario
    • 8.4.4.5. Competitive Scenario
  • 8.4.5. South Korea
    • 8.4.5.1. South Korea Liquid Biopsy For Early Cancer Detection And Monitoring Market, 2021 - 2033 (USD Million)
    • 8.4.5.2. Key Country Dynamics
    • 8.4.5.3. Regulatory Framework
    • 8.4.5.4. Reimbursement Scenario
    • 8.4.5.5. Competitive Scenario
  • 8.4.6. Thailand
    • 8.4.6.1. Thailand Liquid Biopsy For Early Cancer Detection And Monitoring Market, 2021 - 2033 (USD Million)
    • 8.4.6.2. Key Country Dynamics
    • 8.4.6.3. Regulatory Framework
    • 8.4.6.4. Reimbursement Scenario
    • 8.4.6.5. Competitive Scenario
  • 8.4.7. Australia
    • 8.4.7.1. Australia Liquid Biopsy For Early Cancer Detection And Monitoring Market, 2021 - 2033 (USD Million)
    • 8.4.7.2. Key Country Dynamics
    • 8.4.7.3. Regulatory Framework
    • 8.4.7.4. Reimbursement Scenario
    • 8.4.7.5. Competitive Scenario
• 8.5. Latin America
  • 8.5.1. Latin America Liquid Biopsy For Early Cancer Detection And Monitoring Market, 2021 - 2033 (USD Million)
  • 8.5.2. Brazil
    • 8.5.2.1. Brazil Liquid Biopsy For Early Cancer Detection And Monitoring Market, 2021 - 2033 (USD Million)
    • 8.5.2.2. Key Country Dynamics
    • 8.5.2.3. Regulatory Framework
    • 8.5.2.4. Reimbursement Scenario
    • 8.5.2.5. Competitive Scenario
  • 8.5.3. Argentina
    • 8.5.3.1. Argentina Liquid Biopsy For Early Cancer Detection And Monitoring Market, 2021 - 2033 (USD Million)
    • 8.5.3.2. Key Country Dynamics
    • 8.5.3.3. Regulatory Framework
    • 8.5.3.4. Reimbursement Scenario
    • 8.5.3.5. Competitive Scenario
• 8.6. MEA
  • 8.6.1. MEA Liquid Biopsy For Early Cancer Detection And Monitoring Market, 2021 - 2033 (USD Million)
  • 8.6.2. South Africa
    • 8.6.2.1. South Africa Liquid Biopsy For Early Cancer Detection And Monitoring Market, 2021 - 2033 (USD Million)
    • 8.6.2.2. Key Country Dynamics
    • 8.6.2.3. Regulatory Framework
    • 8.6.2.4. Reimbursement Scenario
    • 8.6.2.5. Competitive Scenario
  • 8.6.3. Saudi Arabia
    • 8.6.3.1. Saudi Arabia Liquid Biopsy For Early Cancer Detection And Monitoring Market, 2021 - 2033 (USD Million)
    • 8.6.3.2. Key Country Dynamics
    • 8.6.3.3. Regulatory Framework
    • 8.6.3.4. Reimbursement Scenario
    • 8.6.3.5. Competitive Scenario
  • 8.6.4. UAE
    • 8.6.4.1. UAE Liquid Biopsy For Early Cancer Detection And Monitoring Market, 2021 - 2033 (USD Million)
    • 8.6.4.2. Key Country Dynamics
    • 8.6.4.3. Regulatory Framework
    • 8.6.4.4. Reimbursement Scenario
    • 8.6.4.5. Competitive Scenario
  • 8.6.5. Kuwait
    • 8.6.5.1. Kuwait Liquid Biopsy For Early Cancer Detection And Monitoring Market, 2021 - 2033 (USD Million)
    • 8.6.5.2. Key Country Dynamics
    • 8.6.5.3. Regulatory Framework
    • 8.6.5.4. Reimbursement Scenario
    • 8.6.5.5. Competitive Scenario

Chapter 9. Competitive Landscape

• 9.1. Company Categorization
• 9.2. Strategy Mapping
  • 9.2.1. New Biomarker Launch
  • 9.2.2. Partnerships
  • 9.2.3. Acquisition
  • 9.2.4. Collaboration
  • 9.2.5. Funding
• 9.3. Key Company Market Share Analysis, 2024
• 9.4. Company Heat Map Analysis
• 9.5. Company Profiles
  • 9.5.1. Grail, Inc.
    • 9.5.1.1. Company Overview
    • 9.5.1.2. Financial Performance
    • 9.5.1.3. Biomarker Benchmarking
    • 9.5.1.4. Strategic Initiatives
  • 9.5.2. Exact Sciences Corporation
    • 9.5.2.1. Company Overview
    • 9.5.2.2. Financial Performance
    • 9.5.2.3. Biomarker Benchmarking
    • 9.5.2.4. Strategic Initiatives
  • 9.5.3. Anchordx
    • 9.5.3.1. Company Overview
    • 9.5.3.2. Financial Performance
    • 9.5.3.3. Biomarker Benchmarking
    • 9.5.3.4. Strategic Initiatives
  • 9.5.4. Burning Rock Biotech Limited
    • 9.5.4.1. Company Overview
    • 9.5.4.2. Financial Performance
    • 9.5.4.3. Biomarker Benchmarking
    • 9.5.4.4. Strategic Initiatives
  • 9.5.5. Genecast
    • 9.5.5.1. Company Overview
    • 9.5.5.2. Financial Performance
    • 9.5.5.3. Biomarker Benchmarking
    • 9.5.5.4. Strategic Initiatives
  • 9.5.6. Guardant Health
    • 9.5.6.1. Company Overview
    • 9.5.6.2. Financial Performance
    • 9.5.6.3. Biomarker Benchmarking
    • 9.5.6.4. Strategic Initiatives
  • 9.5.7. Myriad Genetics, Inc.
    • 9.5.7.1. Company Overview
    • 9.5.7.2. Financial Performance
    • 9.5.7.3. Biomarker Benchmarking
    • 9.5.7.4. Strategic Initiatives
  • 9.5.8. Elypta Ab
    • 9.5.8.1. Company Overview
    • 9.5.8.2. Financial Performance
    • 9.5.8.3. Biomarker Benchmarking
    • 9.5.8.4. Strategic Initiatives
  • 9.5.9. Lucence Health Inc.
    • 9.5.9.1. Company Overview
    • 9.5.9.2. Financial Performance
    • 9.5.9.3. Biomarker Benchmarking
    • 9.5.9.4. Strategic Initiatives
  • 9.5.10. Freenome Holdings, Inc.
    • 9.5.10.1. Company Overview
    • 9.5.10.2. Financial Performance
    • 9.5.10.3. Biomarker Benchmarking
    • 9.5.10.4. Strategic Initiatives
  • 9.5.11. Oncimmune
    • 9.5.11.1. Company Overview
    • 9.5.11.2. Financial Performance
    • 9.5.11.3. Biomarker Benchmarking
    • 9.5.11.4. Strategic Initiatives